Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons

Neuron

Volumn 62, Issue 2, 2009, Pages 218-229

  Mosharov, Eugene V ^a   Larsen, Kristin E ^a   Kanter, Ellen ^a   Phillips, Kester A ^a   Wilson, Krystal ^a   Schmitz, Yvonne ^a   Krantz, David E ^b   Kobayashi, Kazuto ^c   Edwards, Robert H ^d   Sulzer, David ^a,e  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBENZYLHYDRAZINE; ALPHA SYNUCLEIN; CALCIUM CHANNEL; CALCIUM ION; COCAINE; DOPAMINE; LEVODOPA; METHAMPHETAMINE; PARGYLINE; RESERPINE; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CALCIUM CELL LEVEL; CELL METABOLISM; CONTROLLED STUDY; CYTOSOL; DISEASE PREDISPOSITION; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; GENE DELETION; MESENCEPHALON; MOUSE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, NEWBORN; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CELL DEATH; CYTOSOL; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCHEMISTRY; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HUMANS; HYDRAZINES; LEVODOPA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 65249180086     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2009.01.033     Document Type: Article

References (77)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., et al. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000) 239-252
2. Abou-Sleiman P.M., Muqit M.M., and Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7 (2006) 207-219
3. Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., Hoglinger G.U., Oertel W.H., and Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice. Exp. Neurol. 210 (2008) 182-193
4. 2-terminal serine 81 phosphorylation site. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H1614-H1622
5. Burke R.E., Antonelli M., and Sulzer D. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J. Neurochem. 71 (1998) 517-525
6. Burke W.J., Li S.W., Chung H.D., Ruggiero D.A., Kristal B.S., Johnson E.M., Lampe P., Kumar V.B., Franko M., Williams E.A., and Zahm D.S. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25 (2004) 101-115
7. Burke W.J., Kumar V.B., Pandey N., Panneton W.M., Gan Q., Franko M.W., O'Dell M., Li S.W., Pan Y., Chung H.D., and Galvin J.E. Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 115 (2008) 193-203
8. Caudle W.M., Colebrooke R.E., Emson P.C., and Miller G.W. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci. 31 (2008) 303-308
9. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., Meredith G.E., and Surmeier D.J. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447 (2007) 1081-1086
10. Chang L., Alicata D., Ernst T., and Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 102 (2007) 16-32
11. Chen J.J., Swope D.M., and Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin. Ther. 29 (2007) 1825-1849
12. Chen L., Ding Y., Cagniard B., Van Laar A.D., Mortimer A., Chi W., Hastings T.G., Kang U.J., and Zhuang X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28 (2008) 425-433
13. Chien J.B., Wallingford R.A., and Ewing A.G. Estimation of free dopamine in the cytoplasm of the giant dopamine cell of Planorbis corneus by voltammetry and capillary electrophoresis. J. Neurochem. 54 (1990) 633-638
14. Clayton D.F., and George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21 (1998) 249-254
15. Colliver T., Hess E., Pothos E.N., Sulzer D., and Ewing A.G. Quantitative and statistical analysis of the shape of amperometric spikes recorded from two populations of cells. J. Neurochem. 74 (2000) 1086-1097
16. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294 (2001) 1346-1349
17. Cubells J.F., Rayport S., Rajendran G., and Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14 (1994) 2260-2271
18. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
19. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 99 (2002) 14524-14529
20. Day M., Wang Z., Ding J., An X., Ingham C.A., Shering A.F., Wokosin D., Ilijic E., Sun Z., Sampson A.R., et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 9 (2006) 251-259
21. Duchemin A.M., Berry M.D., Neff N.H., and Hadjiconstantinou M. Phosphorylation and activation of brain aromatic L-amino acid decarboxylase by cyclic AMP-dependent protein kinase. J. Neurochem. 75 (2000) 725-731
22. Dunkley P.R., Bobrovskaya L., Graham M.E., von Nagy-Felsobuki E.I., and Dickson P.W. Tyrosine hydroxylase phosphorylation: regulation and consequences. J. Neurochem. 91 (2004) 1025-1043
23. Edwards R.H. Neural degeneration and the transport of neurotransmitters. Ann. Neurol. 34 (1993) 638-645
24. Eisenhofer G., Kopin I.J., and Goldstein D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 56 (2004) 331-349
25. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J. Neurol. 252 (2005) IV37-IV42
26. Feigin A., Fukuda M., Dhawan V., Przedborski S., Jackson-Lewis V., Mentis M.J., Moeller J.R., and Eidelberg D. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 57 (2001) 2083-2088
27. Gao H.-M., Kotzbauer P., Uryu K., Leight S., Trojanowski J., and Lee V. Neuroinflammation and oxidation/nitration of α-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28 (2008) 7687-7698
28. Gerfen C.R., Baimbridge K.G., and Miller J.J. The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. Natl. Acad. Sci. USA 82 (1985) 8780-8784
29. Han S.K., Mytilineou C., and Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem. 66 (1996) 501-510
30. Hauser R.A., Lew M.F., Hurtig H.I., Ondo W.G., Wojcieszek J., and Fitzer-Attas C.J. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov. Disord. (2008) 10.1002/mds.22402 in press. Published online December 11, 2008
31. Hirsch E., Graybiel A.M., and Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988) 345-348
32. Isobe C., Abe T., Kikuchi T., Murata T., Sato C., and Terayama Y. Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease. Eur. J. Neurol. 13 (2006) 346-350
33. Jaffe E.H., Marty A., Schulte A., and Chow R.H. Extrasynaptic vesicular transmitter release from the somata of substantia nigra neurons in rat midbrain slices. J. Neurosci. 18 (1998) 3548-3553
34. Jeon M.Y., Lee W.Y., Kang H.Y., and Chung E.J. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models. Neurol. Res. 29 (2007) 289-295
35. Kahlig K.M., Binda F., Khoshbouei H., Blakely R.D., McMahon D.G., Javitch J.A., and Galli A. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc. Natl. Acad. Sci. USA 102 (2005) 3495-3500
36. Krantz D.E., Peter D., Liu Y., and Edwards R.H. Phosphorylation of a vesicular monoamine transporter by casein kinase II. J. Biol. Chem. 272 (1997) 6752-6759
37. Larsen K.E., Fon E.A., Hastings T.G., Edwards R.H., and Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22 (2002) 8951-8960
38. LaVoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., and Selkoe D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11 (2005) 1214-1221
39. Li H., Waites C.L., Staal R.G., Dobryy Y., Park J., Sulzer D.L., and Edwards R.H. Sorting of vesicular monoamine transporter 2 to the regulated secretory pathway confers the somatodendritic exocytosis of monoamines. Neuron 48 (2005) 619-633
40. Liang C.L., Nelson O., Yazdani U., Pasbakhsh P., and German D.C. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J. Comp. Neurol. 473 (2004) 97-106
41. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., and Brundin P. Effect of mutant α-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277 (2002) 38884-38894
42. Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A.C., Mazzulli J., Mosharov E.V., Hodara R., Fredenburg R., Wu D.C., Follenzi A., et al. Dopamine-modified α-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118 (2008) 777-788
43. Mena M.A., Davila V., and Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J. Neurochem. 69 (1997) 1398-1408
44. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005) 57-87
45. Mosharov E.V., Gong L.W., Khanna B., Sulzer D., and Lindau M. Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells. J. Neurosci. 23 (2003) 5835-5845
46. Mosharov E.V., Staal R.G., Bove J., Prou D., Hananiya A., Markov D., Poulsen N., Larsen K.E., Moore C.M., Troyer M.D., et al. α-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci. 26 (2006) 9304-9311
47. Moszczynska A., Fitzmaurice P., Ang L., Kalasinsky K.S., Schmunk G.A., Peretti F.J., Aiken S.S., Wickham D.J., and Kish S.J. Why is parkinsonism not a feature of human methamphetamine users?. Brain 127 (2004) 363-370
48. 2+ conductances in guinea-pig substantia nigra pars compacta neurones. J. Physiol. 466 (1993) 727-747
49. Nicholson C. Diffusion of ions and macromolecules in brain tissue. In: Rollema H., Abercrombie E., Sulzer D., and Zackheim J. (Eds). Monitoring Molecules in Neuroscience (1999), Rutgers University Press, Newark, NJ 71-73
50. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., De Yebenes J., Gershanik O., Guttman M., Grandas F., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord. 19 (2004) 997-1005
51. Pardo B., Mena M.A., Casarejos M.J., Paino C.L., and De Yebenes J.G. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 682 (1995) 133-143
52. Pothos E.N., Davila V., and Sulzer D. Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size. J. Neurosci. 18 (1998) 4106-4118
53. Pothos E.N., Larsen K.E., Krantz D.E., Liu Y., Haycock J.W., Setlik W., Gershon M.D., Edwards R.H., and Sulzer D. Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J. Neurosci. 20 (2000) 7297-7306
54. Rajadhyaksha A.M., and Kosofsky B.E. Psychostimulants, L-type calcium channels, kinases, and phosphatases. Neuroscientist 11 (2005) 494-502
55. 2+ channels mediate adaptation of extracellular signal-regulated kinase 1/2 phosphorylation in the ventral tegmental area after chronic amphetamine treatment. J. Neurosci. 24 (2004) 7464-7476
56. Rayport S., Sulzer D., Shi W.X., Sawasdikosol S., Monaco J., Batson D., and Rajendran G. Identified postnatal mesolimbic dopamine neurons in culture: morphology and electrophysiology. J. Neurosci. 12 (1992) 4264-4280
57. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., and Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235 (1982) 93-103
58. Rice M.E., Cragg S.J., and Greenfield S.A. Characteristics of electrically evoked somatodendritic dopamine release in substantia nigra and ventral tegmental area in vitro. J. Neurophysiol. 77 (1997) 853-862
59. Sampaio-Maia B., Serrao M.P., and Soares-da-Silva P. Regulatory pathways and uptake of L-DOPA by capillary cerebral endothelial cells, astrocytes, and neuronal cells. Am. J. Physiol. Cell Physiol. 280 (2001) C333-C342
60. Sang T.K., Chang H.Y., Lawless G.M., Ratnaparkhi A., Mee L., Ackerson L.C., Maidment N.T., Krantz D.E., and Jackson G.R. A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. J. Neurosci. 27 (2007) 981-992
61. Sawamoto K., Nakao N., Kobayashi K., Matsushita N., Takahashi H., Kakishita K., Yamamoto A., Yoshizaki T., Terashima T., Murakami F., et al. Visualization, direct isolation, and transplantation of midbrain dopaminergic neurons. Proc. Natl. Acad. Sci. USA 98 (2001) 6423-6428
62. 2+ channel isoforms for brain function. Biochem. Soc. Trans. 34 (2006) 903-909
63. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 30 (2007) 244-250
64. Sulzer D., and Pothos E.N. Regulation of quantal size by presynaptic mechanisms. Rev. Neurosci. 11 (2000) 159-212
65. Sulzer D., and Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res. 1 (2000) 181-195
66. Sulzer D., Bogulavsky J., Larsen K.E., Behr G., Karatekin E., Kleinman M.H., Turro N., Krantz D., Edwards R.H., Greene L.A., and Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. USA 97 (2000) 11869-11874
67. Sulzer D., Sonders M.S., Poulsen N.W., and Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75 (2005) 406-433
68. Sulzer D., Mosharov E., Talloczy Z., Zucca F.A., Simon J.D., and Zecca L. Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J. Neurochem. 106 (2008) 24-36
69. Surmeier D.J. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 6 (2007) 933-938
70. Thompson L., Barraud P., Andersson E., Kirik D., and Bjorklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J. Neurosci. 25 (2005) 6467-6477
71. Tohgi H., Abe T., Yamazaki K., Saheki M., Takahashi S., and Tsukamoto Y. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci. Lett. 192 (1995) 165-168
72. Tohgi H., Abe T., Saheki M., Yamazaki K., and Murata T. Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patients. J. Neural Transm. 104 (1997) 441-449
73. Ved R., Saha S., Westlund B., Perier C., Burnam L., Sluder A., Hoener M., Rodrigues C.M., Alfonso A., Steer C., et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of α-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem. 280 (2005) 42655-42668
74. Wightman R.M., Jankowski J.A., Kennedy R.T., Kawagoe K.T., Schroeder T.J., Leszczyszyn D.J., Near J.A., Diliberto Jr. E.J., and Viveros O.H. Temporally resolved catecholamine spikes correspond to single vesicle release from individual chromaffin cells. Proc. Natl. Acad. Sci. USA 88 (1991) 10754-10758
75. Williams J.T., North R.A., Shefner S.A., Nishi S., and Egan T.M. Membrane properties of rat locus coeruleus neurones. Neuroscience 13 (1984) 137-156
76. Young E.A., Duchemin A.M., Neff N.H., and Hadjiconstantinou M. Parallel modulation of striatal dopamine synthetic enzymes by second messenger pathways. Eur. J. Pharmacol. 357 (1998) 15-23
77. Zecca L., Tampellini D., Gerlach M., Riederer P., Fariello R.G., and Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol. Pathol. 54 (2001) 414-418